MetLife Investment Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the third quarter worth about $123,000. Avanza Fonder AB purchased a new stake in shares of Corbus ...

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human ...

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals ... Fein covers the Healthcare sector, focusing on stocks such as Palvella ...

The building had housed various businesses over the years, including Corbus LLC, whose name featured prominently on its side. ExploreWest Carrollton hopes to clean up waste site, create adventure ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study ...

Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP ... Amin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Apellis ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.18% to $10.15 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced on Tuesday that it will present updated data from its Phase 1 dose escalation study of CRB-701 or SYS6002 at the 2025 American ...